While these results support the integration of SYK and BTK inhibitors into the treatment paradigm for adult ITP—particularly in patients with inadequate responses or intolerance to conventional therapies, such as corticosteroids, TPO-RAs, and rituximab— direct head-to-head comparisons with established treatments are currently unavailable, limiting definitive conclusions about their optimal sequencing or relative effectiveness.7 This evidence concerns the gene BTK and autoimmune thrombocytopenic purpura.